Last reviewed · How we verify
CD19-targeted CART cells
At a glance
| Generic name | CD19-targeted CART cells |
|---|---|
| Sponsor | jiuwei cui |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (PHASE3)
- UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases (EARLY_PHASE1)
- A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) (PHASE1)
- Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (EARLY_PHASE1)
- Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases (EARLY_PHASE1)
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases (EARLY_PHASE1)
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1)
- Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |